Bristol Myers Squibb in collaboration with Johnson & Johnson today announced the decision to stop the Phase 3 Librexia ACS trial evaluating the efficacy and safety of milvexian when added to the ...
The phase 3 Librexia ACS trial evaluating the safety and efficacy of milvexian after a recent acute coronary syndrome has been discontinued.
Papillary muscle scarring (papSCAR) as detected by dark blood delayed-enhancement cardiovascular magnetic resonance (CMR) was ...
Professor Derek Yellon discusses the increasing prevalence of cardiovascular diseases (CVD) in Africa and the associated treatment challenges ...
Patients with stroke who receive intra-arterial thrombolysis after thrombectomy are more likely to achieve superior 90-day ...
15d
Scientists have pointed to the ability of cocoa to protect blood vessels during prolonged sitting
Sitting has a negative impact on human health, but a new study has shown that cocoa compounds called flavanols block harmful effects on blood vessels. This was reported by New Atlas magazine on ...
Background The epidemiology of sudden cardiac arrest (SCA) in the Mediterranean area remains unclear. The aim of this study ...
The benefit of beta-blockers after myocardial infarction in patients with a preserved left ventricular ejection fraction ...
There is a bidirectional association between myocardial infarction (MI) and late-onset epilepsy (LOE), according to a study ...
A major analysis led by the Centro Nacional de Investigaciones Cardiovasculares (CNIC), in collaboration with international institutions, has pooled data from 17,801 myocardial infarction survivors ...
Hypereosinophilic syndrome (HES) is a heterogeneous disorder characterised by persistent, abnormal eosinophil elevation in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback